ReAlta Life Sciences Overview
- Status
-
Private
- Employees
-
25

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$30M
- Investors
-
9
ReAlta Life Sciences General Information
Description
Developer of drugs intended to save lives by rebalancing the inflammatory response to address life-threatening acute and rare diseases. The company's peptides are based on research into the human astrovirus, which causes non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system and leveraging these virus-derived mechanisms to rebalance complement and inflammatory processes in the body, enabling healthcare professionals to address medical needs through beneficial inhibition of the complement system and inflammatory mechanisms.
Contact Information
Website
www.realtalifesciences.comCorporate Office
- 5665 Lowery Road
- Suite 100
- Norfolk, VA 23502
- United States
Corporate Office
- 5665 Lowery Road
- Suite 100
- Norfolk, VA 23502
- United States
ReAlta Life Sciences Timeline
ReAlta Life Sciences Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Later Stage VC (Series A) | 06-Nov-2023 | $30M | Completed | Clinical Trials - Phase 2 | ||
6. Later Stage VC (Series A) | 13-Sep-2023 | Completed | Clinical Trials - Phase 2 | |||
5. Grant | 08-Jun-2021 | Completed | Clinical Trials - Phase 1 | |||
4. Early Stage VC (Series A3) | 28-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
3. Early Stage VC (Series A) | 21-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
2. Early Stage VC (Series A) | 28-Oct-2019 | $12M | $12M | Completed | Clinical Trials - General | |
1. Grant | 06-Jun-2019 | $4.4M | Completed | Clinical Trials - General |
ReAlta Life Sciences Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A5 | ||||||||
Series A4 | ||||||||
Series A3 | 428,327 | $0.010000 | $52.53 | $52.53 | 1x | $52.53 | 12.95% | |
Series A | 764,706 | $0.010000 | $34 | $34 | 1x | $34 | 23.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ReAlta Life Sciences Comparisons
Industry
Financing
Details
ReAlta Life Sciences Competitors (63)
One of ReAlta Life Sciences’s 63 competitors is Qu Biologics, a Venture Capital-Backed company based in Burnaby, Canada.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Qu Biologics | Venture Capital-Backed | Burnaby, Canada | ||||
Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
Evommune | Venture Capital-Backed | Palo Alto, CA | ||||
Visterra | Formerly VC-backed | Waltham, MA | ||||
Mozart Therapeutics | Venture Capital-Backed | Seattle, WA |
ReAlta Life Sciences Patents
ReAlta Life Sciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2022286333-A1 | Peptides and methods of use | Pending | 01-Jun-2021 | ||
CA-3215620-A1 | Peptides and methods of use | Pending | 01-Jun-2021 | ||
US-20240209036-A1 | Peptides and methods of use | Pending | 01-Jun-2021 | ||
EP-4346866-A1 | Peptides and methods of use | Pending | 01-Jun-2021 | ||
AU-2022286333-A9 | Peptides and methods of use | Pending | 01-Jun-2021 | C07K14/08 |
ReAlta Life Sciences Signals
ReAlta Life Sciences Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Koa Labs | Venture Capital | Minority | ||
Children's Research Holdings | Other | Minority | ||
Eriko Life Science Ventures | Venture Capital | Minority | ||
Marathon Pharmaceuticals | Corporation | Minority | ||
Commonwealth Research Commercialization Fund | Government |
ReAlta Life Sciences FAQs
-
Where is ReAlta Life Sciences headquartered?
ReAlta Life Sciences is headquartered in Norfolk, VA.
-
What is the size of ReAlta Life Sciences?
ReAlta Life Sciences has 25 total employees.
-
What industry is ReAlta Life Sciences in?
ReAlta Life Sciences’s primary industry is Drug Discovery.
-
Is ReAlta Life Sciences a private or public company?
ReAlta Life Sciences is a Private company.
-
What is the current valuation of ReAlta Life Sciences?
The current valuation of ReAlta Life Sciences is
. -
What is ReAlta Life Sciences’s current revenue?
The current revenue for ReAlta Life Sciences is
. -
How much funding has ReAlta Life Sciences raised over time?
ReAlta Life Sciences has raised $90.5M.
-
Who are ReAlta Life Sciences’s investors?
Koa Labs, Children's Research Holdings, Eriko Life Science Ventures, Marathon Pharmaceuticals, and Commonwealth Research Commercialization Fund are 5 of 9 investors who have invested in ReAlta Life Sciences.
-
Who are ReAlta Life Sciences’s competitors?
Qu Biologics, Cristal Therapeutics, Evommune, Visterra, and Mozart Therapeutics are some of the 63 competitors of ReAlta Life Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »